Amgen Inc.
AMGN
주식 순위
#73
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
주가
$432.40
마지막 동기화: 2026-10-16
시가총액
$233.77B
변동 (1일)
-0.38%
변동 (1년)
44.71%
국가
US
거래 Amgen Inc. (AMGN)
카테고리
Healthcare
Amgen Inc. (AMGN)의 영업이익률
October 2026 기준 영업이익률 TTM: 33.18%
Amgen Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 33.18%입니다. 2024년 말 기준 영업이익률은 21.71%였습니다.
Amgen Inc.의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 33.18% | -18.11% |
| 2025 | 40.52% | 86.64% |
| 2024 | 21.71% | -22.49% |
| 2023 | 28.01% | -22.92% |
| 2022 | 36.34% | 23.61% |
| 2021 | 29.40% | -18.22% |
| 2020 | 35.95% | -13.19% |
| 2019 | 41.41% | -4.19% |
| 2018 | 43.22% | -0.99% |
| 2017 | 43.65% | 2.46% |
| 2016 | 42.60% | 8.95% |
| 2015 | 39.10% | 26.70% |
| 2014 | 30.86% | -1.75% |
| 2013 | 31.41% | -2.76% |
| 2012 | 32.30% | 16.73% |
| 2011 | 27.67% | -24.89% |
| 2010 | 36.84% | -2.02% |
| 2009 | 37.60% | 8.20% |
| 2008 | 34.75% | 28.99% |
| 2007 | 26.94% | 0.11% |
| 2006 | 26.91% | -31.00% |
| 2005 | 39.00% | 22.91% |
| 2004 | 31.73% | -14.22% |
| 2003 | 36.99% | -360.31% |
| 2002 | -14.21% | -137.27% |
| 2001 | 38.13% | -3.88% |
| 2000 | 39.67% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 49.72% | -98.50% |
US
|
|
| 25.70% | -99.23% |
US
|
|
| 29.32% | -99.12% |
US
|
|
| 26.59% | -99.20% |
CH
|
|
| 16.65% | -99.50% |
US
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.